Compare PLAB & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLAB | PHVS |
|---|---|---|
| Founded | 1969 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 1995 | 2020 |
| Metric | PLAB | PHVS |
|---|---|---|
| Price | $48.07 | $28.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $44.33 | $41.82 |
| AVG Volume (30 Days) | ★ 803.7K | 203.5K |
| Earning Date | 05-27-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.09 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $535,276,000.00 | N/A |
| Revenue This Year | $6.70 | N/A |
| Revenue Next Year | $4.96 | N/A |
| P/E Ratio | $69.43 | ★ N/A |
| Revenue Growth | ★ 18.77 | N/A |
| 52 Week Low | $16.59 | $15.51 |
| 52 Week High | $52.79 | $30.24 |
| Indicator | PLAB | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 59.48 | 51.80 |
| Support Level | $21.30 | $24.55 |
| Resistance Level | N/A | $29.82 |
| Average True Range (ATR) | 2.05 | 1.40 |
| MACD | 0.17 | -0.05 |
| Stochastic Oscillator | 49.74 | 55.84 |
Photronics Inc is a U.S.-based company principally engaged in the manufacturing of photomasks, which are high-precision photographic quartz or glass plates containing microscopic images of electronic circuits. Photomasks are a key element in the manufacture of integrated circuits (ICs) and flat-panel displays (FPDs) and are used as masters to transfer circuit patterns onto semiconductor wafers and FPD substrates during fabrication, as well as to a lesser extent, other types of electrical and optical components. The Company has manufacturing facilities in Taiwan, China, South Korea, the United States, and Europe, and generates revenue globally, with Taiwan contributing the majority of total revenue.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.